Literature DB >> 24394630

Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.

Hao-Yuan Lee1, Chyi-Liang Chen, Si-Ru Wu, Chih-Wei Huang, Cheng-Hsun Chiu.   

Abstract

OBJECTIVES: Acinetobacter baumannii complex bacteremia has been identified increasingly in critical patients admitted in ICUs. Notably, A. baumannii complex bacteremia has a high mortality rate, yet the risk factors associated with mortality remain unclear and controversial.
DESIGN: Retrospective study.
SETTING: All adult ICUs at a tertiary care medical center. PATIENTS: All patients with A. baumannii complex bacteremia admitted in 2009-2010.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Risk factors for mortality were analyzed. Bacterial isolates were identified by 16S-23S ribosomal RNA intergenic spacer region sequencing for genospecies and genotyped by pulsed-field gel electrophoresis. Carbapenemase genes were detected by polymerase chain reaction and sequencing. A total of 298 patients met the inclusion criteria, including 73 (24.5%) infected by imipenem-resistant A. baumannii complex. The overall 30-day mortality was 33.6% (100 of 298). Imipenem-resistant A. baumannii complex bacteremia specifically showed a high mortality (69.9%) and was associated with prior use of broad-spectrum antibiotics for more than 5 days for treating ventilator-associated pneumonia before the occurrence of bacteremia. Mortality was associated with inappropriate initial antimicrobial therapy, which was correlated with imipenem-resistant A. baumannii complex but not with any specific genospecies. ISAba1-blaOXA-23-ISAba1 (Tn2006) was found in most (66.7%, 40 of 68) imipenem-resistant A. baumannii (genospecies 2) and also spread beyond species border to all imipenem-resistant genospecies 3 (2), 13TU (2), and 10 (1).
CONCLUSIONS: For critical patients with A. baumannii complex infection, ventilator-associated pneumonia in particular, the selective pressure from prior use of broad-spectrum antibiotics for 5 days or more increased risk of subsequent imipenem-resistant A. baumannii complex bacteremia. To reduce mortality, rapid identification of imipenem-resistant A. baumannii complex and early initiation of appropriate antimicrobial therapy in these high-risk patients are crucial.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24394630     DOI: 10.1097/CCM.0000000000000125

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  42 in total

1.  Crystal structure of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase from the ESKAPE pathogen Acinetobacter baumannii.

Authors:  Kristin A Sutton; Jennifer Breen; Thomas A Russo; L Wayne Schultz; Timothy C Umland
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-02-16       Impact factor: 1.056

Review 2.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 3.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

5.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

6.  An ompR-envZ Two-Component System Ortholog Regulates Phase Variation, Osmotic Tolerance, Motility, and Virulence in Acinetobacter baumannii Strain AB5075.

Authors:  Kyle A Tipton; Philip N Rather
Journal:  J Bacteriol       Date:  2017-01-12       Impact factor: 3.490

7.  A three-point time series study of antibiotic usage on an intensive care unit, following an antibiotic stewardship programme, after an outbreak of multi-resistant Acinetobacter baumannii.

Authors:  S Singh; Y Z Zhang; S Chalkley; K Ananthan; E Demertzi; M Beach; M Cohen; V Grover; C Chung; J Tatlock; N Soni; B Azadian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-05       Impact factor: 3.267

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

9.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

Review 10.  Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity.

Authors:  A M Richards; Y Abu Kwaik; R J Lamont
Journal:  Mol Oral Microbiol       Date:  2014-09-27       Impact factor: 3.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.